Peter Kufer
63Patents
16h-index
80Co-inventors
87Inventor score
Filing activity: Apr 14, 1998 → Sep 20, 2021
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8236308B2 | Composition comprising cross-species-specific antibodies and uses thereof | Chemistry; Metallurgy | 175 | Active |
| US7112324B1 | CD 19×CD3 specific polypeptides and uses thereof | Chemistry; Metallurgy | 130 | Expired |
| US7635472B2 | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders | Chemistry; Metallurgy | 87 | Expired |
| US7235641B2 | Bispecific antibodies | Chemistry; Metallurgy | 77 | Expired |
| US8784821B1 | Human-anti-human cd3 binding molecules | Chemistry; Metallurgy | 56 | Active |
| US9150664B2 | Binding molecules for BCMA and CD3 | Chemistry; Metallurgy | 54 | Active |
| US9340621B2 | Binding molecules for BCMA and CD3 | Chemistry; Metallurgy | 51 | Active |
| US7575923B2 | CD19xCD3 specific polypeptides and uses thereof | Chemistry; Metallurgy | 48 | Expired |
| US7227002B1 | Human antibodies that bind human 17-A1/EpCAM tumor antigen | Chemistry; Metallurgy | 36 | Expired |
| US8101722B2 | Less immunogenic binding molecules | Chemistry; Metallurgy | 35 | Active |
| US10294300B2 | Antibody constructs for DLL3 and CD3 | Chemistry; Metallurgy | 28 | Active |
| US8007796B2 | Means and methods for the treatment of tumorous diseases | Chemistry; Metallurgy | 28 | Active |
| US9587036B2 | Cross-species-specific PSMAxCD3 bispecific single chain antibody | Chemistry; Metallurgy | 23 | Active |
| US8394926B2 | Pharmaceutical compositions with resistance to soluble CEA | Chemistry; Metallurgy | 18 | Active |
| US9598500B2 | Binding molecules for BCMA and CD3 | Chemistry; Metallurgy | 17 | Active |
| US8840888B2 | Dosage regimen for administering a CD19XCD3 bispecific antibody | Physics | 17 | Active |
| US10301391B2 | BCMA and CD3 bispecific T cell engaging antibody constructs | Chemistry; Metallurgy | 16 | Active |
| US7919089B2 | Pharmaceutical composition comprising a bispecific antibody for EpCAM | Emerging Cross-Sectional Technologies | 16 | Expired |
| US10519241B2 | Antibody constructs for EGFRVIII and CD3 | Chemistry; Metallurgy | 14 | Active |
| US9688760B2 | Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domains | Chemistry; Metallurgy | 13 | Active |
| US7435549B1 | Method of identifying binding site domains that retain the capacity of binding to an epitope | Chemistry; Metallurgy | 11 | Expired |
| US9765157B2 | Antibody constructs for CDH19 and CD3 | Chemistry; Metallurgy | 10 | Active |
| US7632925B2 | Antibodies that bind human 17-A1/EpCAM tumor antigen | Chemistry; Metallurgy | 10 | Active |
| US8790645B2 | Pharmaceutical composition comprising a bispecific antibody for EpCAM | Emerging Cross-Sectional Technologies | 9 | Active |
| US10781264B2 | PSMA and CD3 bispecific T cell engaging antibody constructs | Chemistry; Metallurgy | 8 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.